# Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

> **NCT01571635** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 46 (actual)

## Conditions studied

- Beta Thalassemia Major
- Beta Thalassemia Intermedia

## Interventions

- **DRUG:** SOTATERCEPT (ACE-011)

## Key facts

- **NCT ID:** NCT01571635
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-10
- **Primary completion:** 2015-07-02
- **Final completion:** 2022-05-24
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01571635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01571635, "Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01571635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*